Hyundai India's Q1 profit fall looks transitory, not structural Automobiles
Hyundai India's MD/CEO said production at the fire-affected Chennai plant has fully normalized and reiterated FY27 guidance of 8-10% volume growth and 11-14% EBITDA margin, supporting the view that the Q1 FY27 35% profit decline was a one-off from the May 2026 Mobis supplier fire rather than a structural franchise issue. Actual Q2 results are not yet out, so this is supportive, not conclusive, evidence.
IOL Chemicals' Q1 results back its capex thesis despite the recent price drop Pharmaceuticals
IOL Chemicals posted 37% YoY revenue growth and an 89.9% PAT surge in Q1 FY27, with non-ibuprofen pharma revenue now 43% of the pharma mix (up from 36%) -- evidence the Rs 495 crore capex plan is converting into growth. A GMP certificate for the new Hungary-inspected CDMO facility and a fresh US FDA nod for its ibuprofen plant add supporting milestones. No company-specific negative catalyst was found to explain the session's -8.10% price move.
Brigade's Chennai EC revocation looks contained so far, but litigation is still live Realty
No further environmental-clearance issues or stop-work orders have surfaced at any other Brigade project since the Morgan Heights (Perumbakkam) revocation, and Brigade is contesting the SEIAA order in the Supreme Court. Sector sentiment has otherwise turned sharply positive, but that improvement -- and a 20% intraday jump in Brigade shares -- is tied to an unrelated Rs 214.71 crore preferential warrant issue to Minerva Ventures Fund, not resolution of the EC matter.
Pine Labs raised FY27 guidance despite a weak Q1 print, but analysts aren't confirming an upgrade yet Financial Services
Pine Labs' Q1 FY27 profit fell 67% QoQ and shares slid on the print, even as management raised FY27 revenue-growth guidance to 21-23.5% and lifted margin guidance. Citi, Morgan Stanley and Emkay all cut price targets while holding their existing ratings -- none moved to an outright positive call, which reads as mixed evidence against the pending AVOID->HOLD confirmation, not for it.
DOMS: the pullback is real but the stock still isn't cheap, and margins just took a hit Retail & Consumer
DOMS is down roughly 29% from its all-time high, but at ~58-59x trailing earnings it is still priced for uninterrupted high-teens growth, and Q1 FY27 EBITDA margin fell to 12.3% from 17.6% on West Asia-linked input inflation. Management calls this the margin trough and has reiterated 18-20% FY27 revenue guidance and a 16-17% FY28 margin target, but that is unproven. Separately, co-promoter FILA has sold down its DOMS stake twice in 18 months, cutting combined promoter holding from 70.4% to 63.4% in a year -- framed as parent-level deleveraging, but worth tracking.